| pubmed-article:2415436 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2415436 | lifeskim:mentions | umls-concept:C0019169 | lld:lifeskim |
| pubmed-article:2415436 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:2415436 | lifeskim:mentions | umls-concept:C0042774 | lld:lifeskim |
| pubmed-article:2415436 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:2415436 | lifeskim:mentions | umls-concept:C0042646 | lld:lifeskim |
| pubmed-article:2415436 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2415436 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:2415436 | lifeskim:mentions | umls-concept:C0750729 | lld:lifeskim |
| pubmed-article:2415436 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:2415436 | pubmed:dateCreated | 1985-12-30 | lld:pubmed |
| pubmed-article:2415436 | pubmed:abstractText | A previous randomized controlled study has shown a 30% rate of HBe antigen/antibody seroconversion within 1 year of a month course of adenine arabinoside-5'-monophosphate; no seroconversion occurred in the control group. In this study of patients derived from the same population, 45 hepatitis B virus carriers with chronic liver disease were randomized to receive either a short (4-week) course of adenine arabinoside-5'-monophosphate, a long (7 to 8-week) course of adenine arabinoside-5'-monophosphate or a 12-week course of lymphoblastoid interferon. Long-lasting suppression of hepatitis B virus replication with disappearance of serum hepatitis B virus DNA and clearance of HBeAg occurred within 12 months of treatment in four patients who received the short course of adenine arabinoside-5'-monophosphate and in five who received interferon. Of the nine responders, four also lost HBsAg. A response to antiviral therapy was accompanied by clinical and biochemical evidence of improvement in liver disease. None of the patients who received a long course of adenine arabinoside-5'-monophosphate responded. Peripheral neuropathy and myalgia were the most serious adverse effect affecting three recipients of the short course of adenine arabinoside-5'-monophosphate and eight recipients of the long course. Thrice weekly administration of interferon was well-tolerated. Further studies to identify the characteristics of the "responder patients" and large-scale controlled trials of antiviral therapy in these subgroups are indicated. | lld:pubmed |
| pubmed-article:2415436 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2415436 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2415436 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2415436 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2415436 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2415436 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2415436 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2415436 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2415436 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2415436 | pubmed:issn | 0270-9139 | lld:pubmed |
| pubmed-article:2415436 | pubmed:author | pubmed-author:LowA GAG | lld:pubmed |
| pubmed-article:2415436 | pubmed:author | pubmed-author:ThomasH CHC | lld:pubmed |
| pubmed-article:2415436 | pubmed:author | pubmed-author:SherlockSS | lld:pubmed |
| pubmed-article:2415436 | pubmed:author | pubmed-author:KarayiannisPP | lld:pubmed |
| pubmed-article:2415436 | pubmed:author | pubmed-author:NovickD MDM | lld:pubmed |
| pubmed-article:2415436 | pubmed:author | pubmed-author:DunkA AAA | lld:pubmed |
| pubmed-article:2415436 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2415436 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:2415436 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2415436 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2415436 | pubmed:pagination | 1132-8 | lld:pubmed |
| pubmed-article:2415436 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:meshHeading | pubmed-meshheading:2415436-... | lld:pubmed |
| pubmed-article:2415436 | pubmed:articleTitle | A randomized study of the effects of adenine arabinoside 5'-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication. | lld:pubmed |
| pubmed-article:2415436 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2415436 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2415436 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2415436 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2415436 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2415436 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2415436 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2415436 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2415436 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2415436 | lld:pubmed |
